APO Research
Talk to an analyst

APO RESEARCH · REPORT

FAPI for Tumor Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global FAPI for Tumor Treatment Market Outlook and Growth Opportunities 2026

29 December 2025193 pages

Choose your research edition.

Industry ResearchFAPI for Tumor Treatment Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal FAPI for Tumor Treatment Industry Growth and Trends Forecast to 203271 pages · $3,450 USDMarket StructureGlobal FAPI for Tumor Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032178 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal FAPI for Tumor Treatment Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal FAPI for Tumor Treatment Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global FAPI for Tumor Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for FAPI for Tumor Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for FAPI for Tumor Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for FAPI for Tumor Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the FAPI for Tumor Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the FAPI for Tumor Treatment market include Clovis Oncology, Bayer and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global FAPI for Tumor Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of FAPI for Tumor Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents FAPI for Tumor Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the FAPI for Tumor Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

FAPI for Tumor Treatment Segment by Company

Clovis Oncology

Bayer

Novartis AG

FAPI for Tumor Treatment Segment by Type

Beta-emitter

Alpha-emitter

FAPI for Tumor Treatment Segment by Application

NSCLC

Pancreatic Cancer

Breast Cancer

Others

FAPI for Tumor Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global FAPI for Tumor Treatment status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions FAPI for Tumor Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify FAPI for Tumor Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze FAPI for Tumor Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FAPI for Tumor Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of FAPI for Tumor Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FAPI for Tumor Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the FAPI for Tumor Treatment market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global FAPI for Tumor Treatment industry.

Chapter 3: Detailed analysis of FAPI for Tumor Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of FAPI for Tumor Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of FAPI for Tumor Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. FAPI for Tumor Treatment Industry Trends Table 2. FAPI for Tumor Treatment Industry Drivers Table 3. FAPI for Tumor Treatment Industry Opportunities and Challenges Table 4. FAPI for Tumor Treatment Industry Restraints Table 5. Global FAPI for Tumor Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global FAPI for Tumor Treatment Revenue Share by Company (2021-2026) Table 7. Global FAPI for Tumor Treatment Sales Volume by Company (K Units) & (2021-2026) Table 8. Global FAPI for Tumor Treatment Sales Volume Share by Company (2021-2026) Table 9. Global FAPI for Tumor Treatment Average Price (US$/Unit) of Company (2021-2026) Table 10. Global FAPI for Tumor Treatment Company Ranking, (2024-2026) & (USD Million) Table 11. Global FAPI for Tumor Treatment Key Company Manufacturing Base & Headquarters Table 12. Global FAPI for Tumor Treatment Company, Product Type & Application Table 13. Global FAPI for Tumor Treatment Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global FAPI for Tumor Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Beta-emitter Table 18. Significant Companies of Alpha-emitter Table 19. Global FAPI for Tumor Treatment Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global FAPI for Tumor Treatment Sales Volume by Type (2021-2026) & (K Units) Table 21. Global FAPI for Tumor Treatment Sales Volume by Type (2027-2032) & (K Units) Table 22. Global FAPI for Tumor Treatment Sales Volume Share by Type (2021-2026) Table 23. Global FAPI for Tumor Treatment Sales Volume Share by Type (2027-2032) Table 24. Global FAPI for Tumor Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global FAPI for Tumor Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global FAPI for Tumor Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global FAPI for Tumor Treatment Sales Value Share by Type (2021-2026) Table 28. Global FAPI for Tumor Treatment Sales Value Share by Type (2027-2032) Table 29. Significant Companies of NSCLC Table 30. Significant Companies of Pancreatic Cancer Table 31. Significant Companies of Breast Cancer Table 32. Significant Companies of Others Table 33. Global FAPI for Tumor Treatment Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global FAPI for Tumor Treatment Sales Volume by Application (2021-2026) & (K Units) Table 35. Global FAPI for Tumor Treatment Sales Volume by Application (2027-2032) & (K Units) Table 36. Global FAPI for Tumor Treatment Sales Volume Share by Application (2021-2026) Table 37. Global FAPI for Tumor Treatment Sales Volume Share by Application (2027-2032) Table 38. Global FAPI for Tumor Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global FAPI for Tumor Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global FAPI for Tumor Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global FAPI for Tumor Treatment Sales Value Share by Application (2021-2026) Table 42. Global FAPI for Tumor Treatment Sales Value Share by Application (2027-2032) Table 43. Global FAPI for Tumor Treatment Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global FAPI for Tumor Treatment Sales by Region (2021-2026) & (K Units) Table 45. Global FAPI for Tumor Treatment Sales Market Share by Region (2021-2026) Table 46. Global FAPI for Tumor Treatment Sales by Region (2027-2032) & (K Units) Table 47. Global FAPI for Tumor Treatment Sales Market Share by Region (2027-2032) Table 48. Global FAPI for Tumor Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global FAPI for Tumor Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global FAPI for Tumor Treatment Sales Value Share by Region (2021-2026) Table 51. Global FAPI for Tumor Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global FAPI for Tumor Treatment Sales Value Share by Region (2027-2032) Table 53. Global FAPI for Tumor Treatment Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global FAPI for Tumor Treatment Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global FAPI for Tumor Treatment Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global FAPI for Tumor Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global FAPI for Tumor Treatment Sales by Country (2021-2026) & (K Units) Table 58. Global FAPI for Tumor Treatment Sales Market Share by Country (2021-2026) Table 59. Global FAPI for Tumor Treatment Sales by Country (2027-2032) & (K Units) Table 60. Global FAPI for Tumor Treatment Sales Market Share by Country (2027-2032) Table 61. Global FAPI for Tumor Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global FAPI for Tumor Treatment Sales Value Market Share by Country (2021-2026) Table 63. Global FAPI for Tumor Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global FAPI for Tumor Treatment Sales Value Market Share by Country (2027-2032) Table 65. Clovis Oncology Company Information Table 66. Clovis Oncology Business Overview Table 67. Clovis Oncology FAPI for Tumor Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Clovis Oncology FAPI for Tumor Treatment Product Portfolio Table 69. Clovis Oncology Recent Development Table 70. Bayer Company Information Table 71. Bayer Business Overview Table 72. Bayer FAPI for Tumor Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Bayer FAPI for Tumor Treatment Product Portfolio Table 74. Bayer Recent Development Table 75. Novartis AG Company Information Table 76. Novartis AG Business Overview Table 77. Novartis AG FAPI for Tumor Treatment Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Novartis AG FAPI for Tumor Treatment Product Portfolio Table 79. Novartis AG Recent Development Table 80. Key Raw Materials Table 81. Raw Materials Key Suppliers Table 82. FAPI for Tumor Treatment Distributors List Table 83. FAPI for Tumor Treatment Customers List Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. FAPI for Tumor Treatment Product Image Figure 2. Global FAPI for Tumor Treatment Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global FAPI for Tumor Treatment Sales Value (2021-2032) & (US$ Million) Figure 4. Global FAPI for Tumor Treatment Sales (2021-2032) & (K Units) Figure 5. Global FAPI for Tumor Treatment Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global FAPI for Tumor Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Beta-emitter Image Figure 10. Alpha-emitter Image Figure 11. Global FAPI for Tumor Treatment Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global FAPI for Tumor Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global FAPI for Tumor Treatment Sales Volume Share by Type (2021-2032) Figure 14. Global FAPI for Tumor Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global FAPI for Tumor Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global FAPI for Tumor Treatment Sales Value Share by Type (2021-2032) Figure 17. NSCLC Image Figure 18. Pancreatic Cancer Image Figure 19. Breast Cancer Image Figure 20. Others Image Figure 21. Global FAPI for Tumor Treatment Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global FAPI for Tumor Treatment Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global FAPI for Tumor Treatment Sales Volume Share by Application (2021-2032) Figure 24. Global FAPI for Tumor Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global FAPI for Tumor Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global FAPI for Tumor Treatment Sales Value Share by Application (2021-2032) Figure 27. Global FAPI for Tumor Treatment Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global FAPI for Tumor Treatment Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global FAPI for Tumor Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global FAPI for Tumor Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America FAPI for Tumor Treatment Sales Value (2021-2032) & (US$ Million) Figure 32. North America FAPI for Tumor Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe FAPI for Tumor Treatment Sales Value (2021-2032) & (US$ Million) Figure 34. Europe FAPI for Tumor Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific FAPI for Tumor Treatment Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific FAPI for Tumor Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America FAPI for Tumor Treatment Sales Value (2021-2032) & (US$ Million) Figure 38. South America FAPI for Tumor Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa FAPI for Tumor Treatment Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa FAPI for Tumor Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. FAPI for Tumor Treatment Value Chain Figure 126. Manufacturing Cost Structure Figure 127. FAPI for Tumor Treatment Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Beta-emitter
  • Alpha-emitter
Applications
  • NSCLC
  • Pancreatic Cancer
  • Breast Cancer
  • Others
Companies covered
  • Clovis Oncology
  • Bayer
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global FAPI for Tumor Treatment Sales Value (2021-2032)
  4. 1.2.2 Global FAPI for Tumor Treatment Sales Volume (2021-2032)
  5. 1.2.3 Global FAPI for Tumor Treatment Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 FAPI for Tumor Treatment Market Dynamics
  1. 2.1 FAPI for Tumor Treatment Industry Trends
  2. 2.2 FAPI for Tumor Treatment Industry Drivers
  3. 2.3 FAPI for Tumor Treatment Industry Opportunities and Challenges
  4. 2.4 FAPI for Tumor Treatment Industry Restraints
3 FAPI for Tumor Treatment Market by Company
  1. 3.1 Global FAPI for Tumor Treatment Company Revenue Ranking in 2025
  2. 3.2 Global FAPI for Tumor Treatment Revenue by Company (2021-2026)
  3. 3.3 Global FAPI for Tumor Treatment Sales Volume by Company (2021-2026)
  4. 3.4 Global FAPI for Tumor Treatment Average Price by Company (2021-2026)
  5. 3.5 Global FAPI for Tumor Treatment Company Ranking (2024-2026)
  6. 3.6 Global FAPI for Tumor Treatment Company Manufacturing Base and Headquarters
  7. 3.7 Global FAPI for Tumor Treatment Company Product Type and Application
  8. 3.8 Global FAPI for Tumor Treatment Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global FAPI for Tumor Treatment Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 FAPI for Tumor Treatment Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 FAPI for Tumor Treatment Market by Type
  1. 4.1 FAPI for Tumor Treatment Type Introduction
  2. 4.1.1 Beta-emitter
  3. 4.1.2 Alpha-emitter
  4. 4.2 Global FAPI for Tumor Treatment Sales Volume by Type
  5. 4.2.1 Global FAPI for Tumor Treatment Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global FAPI for Tumor Treatment Sales Volume by Type (2021-2032)
  7. 4.2.3 Global FAPI for Tumor Treatment Sales Volume Share by Type (2021-2032)
  8. 4.3 Global FAPI for Tumor Treatment Sales Value by Type
  9. 4.3.1 Global FAPI for Tumor Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global FAPI for Tumor Treatment Sales Value by Type (2021-2032)
  11. 4.3.3 Global FAPI for Tumor Treatment Sales Value Share by Type (2021-2032)
5 FAPI for Tumor Treatment Market by Application
  1. 5.1 FAPI for Tumor Treatment Application Introduction
  2. 5.1.1 NSCLC
  3. 5.1.2 Pancreatic Cancer
  4. 5.1.3 Breast Cancer
  5. 5.1.4 Others
  6. 5.2 Global FAPI for Tumor Treatment Sales Volume by Application
  7. 5.2.1 Global FAPI for Tumor Treatment Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global FAPI for Tumor Treatment Sales Volume by Application (2021-2032)
  9. 5.2.3 Global FAPI for Tumor Treatment Sales Volume Share by Application (2021-2032)
  10. 5.3 Global FAPI for Tumor Treatment Sales Value by Application
  11. 5.3.1 Global FAPI for Tumor Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global FAPI for Tumor Treatment Sales Value by Application (2021-2032)
  13. 5.3.3 Global FAPI for Tumor Treatment Sales Value Share by Application (2021-2032)
6 FAPI for Tumor Treatment Regional Sales and Value Analysis
  1. 6.1 Global FAPI for Tumor Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global FAPI for Tumor Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global FAPI for Tumor Treatment Sales by Region: 2021-2026
  4. 6.2.2 Global FAPI for Tumor Treatment Sales by Region (2027-2032)
  5. 6.3 Global FAPI for Tumor Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global FAPI for Tumor Treatment Sales Value by Region (2021-2032)
  7. 6.4.1 Global FAPI for Tumor Treatment Sales Value by Region: 2021-2026
  8. 6.4.2 Global FAPI for Tumor Treatment Sales Value by Region (2027-2032)
  9. 6.5 Global FAPI for Tumor Treatment Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America FAPI for Tumor Treatment Sales Value (2021-2032)
  12. 6.6.2 North America FAPI for Tumor Treatment Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe FAPI for Tumor Treatment Sales Value (2021-2032)
  15. 6.7.2 Europe FAPI for Tumor Treatment Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific FAPI for Tumor Treatment Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific FAPI for Tumor Treatment Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America FAPI for Tumor Treatment Sales Value (2021-2032)
  21. 6.9.2 South America FAPI for Tumor Treatment Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa FAPI for Tumor Treatment Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa FAPI for Tumor Treatment Sales Value Share by Country, 2025 VS 2032
7 FAPI for Tumor Treatment Country-level Sales and Value Analysis
  1. 7.1 Global FAPI for Tumor Treatment Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global FAPI for Tumor Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global FAPI for Tumor Treatment Sales by Country (2021-2032)
  4. 7.3.1 Global FAPI for Tumor Treatment Sales by Country (2021-2026)
  5. 7.3.2 Global FAPI for Tumor Treatment Sales by Country (2027-2032)
  6. 7.4 Global FAPI for Tumor Treatment Sales Value by Country (2021-2032)
  7. 7.4.1 Global FAPI for Tumor Treatment Sales Value by Country (2021-2026)
  8. 7.4.2 Global FAPI for Tumor Treatment Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt FAPI for Tumor Treatment Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt FAPI for Tumor Treatment Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt FAPI for Tumor Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Clovis Oncology
  2. 8.1.1 Clovis Oncology Company Information
  3. 8.1.2 Clovis Oncology Business Overview
  4. 8.1.3 Clovis Oncology FAPI for Tumor Treatment Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Clovis Oncology FAPI for Tumor Treatment Product Portfolio
  6. 8.1.5 Clovis Oncology Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer FAPI for Tumor Treatment Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Bayer FAPI for Tumor Treatment Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 Novartis AG
  14. 8.3.1 Novartis AG Company Information
  15. 8.3.2 Novartis AG Business Overview
  16. 8.3.3 Novartis AG FAPI for Tumor Treatment Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis AG FAPI for Tumor Treatment Product Portfolio
  18. 8.3.5 Novartis AG Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 FAPI for Tumor Treatment Value Chain Analysis
  2. 9.1.1 FAPI for Tumor Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 FAPI for Tumor Treatment Sales Mode & Process
  6. 9.2 FAPI for Tumor Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 FAPI for Tumor Treatment Distributors
  9. 9.2.3 FAPI for Tumor Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst